Making decisions to introduce or change cancer screening that are based on observed evidence is not straight forward. Even if there is evidence available from randomised controlled trials that clearly proves a reduction in mortality from the cancer in question, there are still several issues to be resolved before an evidence based decision can be made on the introduction or change of a screening programme. One of the factors is cost effectiveness.

, , , ,
Maas, Prof. Dr. P.J. van der (promotor), Ministerie van Volksgezondheid
P.J. van der Maas (Paul)
Erasmus University Rotterdam
Erasmus MC: University Medical Center Rotterdam

Boer, R. (2000, June 28). From Evidence to Decision Support in Cancer Screening; Application of Miscan Models. Retrieved from